Get started
GENOCEA BIOSCIENCES INC COM USD0.001(POST REV SPLIT)GENOCEA BIOSCIENCES INC COM USD0.001(POST REV SPLIT)GENOCEA BIOSCIENCES INC COM USD0.001(POST REV SPLIT)

GENOCEA BIOSCIENCES INC COM USD0.001(POST REV SPLIT)

No trades
See on Supercharts
Overview
Financials
Discussions Technicals Seasonals

0A51 fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The firm uses its proprietary technology platform, ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-011, an investigational adoptive T cell therapy and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

0A51 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company